Event Brief
Aug 5, 2026 at 8:11 AM ET
SIL204 enters Phase 2/3 for KRAS-driven tumors
By The BriefBrief
SIL204 advanced into Phase 2/3 evaluation and began its first clinical trial at Tel Aviv Sourasky Medical Center.
WHO: Silexion
WHAT: SIL204 advanced into Phase 2/3 clinical evaluation and began its first clinical trial at Tel Aviv Sourasky Medical Center.
WHEN: Reported Aug 5, 2026 at 10:38 AM ET
WHERE: Israel
WHY: Cause not yet established.
Reporting from 1 identified publisher for this event.
View all 1 publishers
Publishers represented across this event arc
These publishers contributed reporting to the broader event history. Not every source addresses the specific development described above.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Yen holds at 157 as markets weigh US-Japan limits
Yen
Aug 5, 2026 at 8:13 AM ET
High Court freezes Finance Committee budget transfers
Middle-East
Aug 5, 2026 at 8:11 AM ET
North Korean missile unit deployed in Russia for Ukraine war
North Korea
Aug 5, 2026 at 8:11 AM ET
Ukraine cannot stop new Russian missile barrage
Ukraine
Aug 5, 2026 at 8:11 AM ET
Page 10781 of 21451
Same format. Every time.
Continue reading — sign in or create a free account with
